Maternal Cardiovascular Adaption to Pregnancy in IVF Patients Following Frozen Embryo Transfer (FET)
Launched by AALBORG UNIVERSITY HOSPITAL · Jun 21, 2024
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This clinical trial is looking at how pregnancy affects the heart and blood circulation in women who undergo in-vitro fertilization (IVF) with frozen embryos. Specifically, the study aims to understand how the absence of a structure called the corpus luteum—important for hormone production early in pregnancy—affects these changes. Researchers will use advanced imaging techniques called magnetic resonance imaging (MRI) to gather this information.
To participate in the trial, women must be under 40 years old, have a body mass index (BMI) below 35, and be undergoing a specific type of embryo transfer (either their own or a donor's) related to IVF. They should not have certain health conditions like polycystic ovary syndrome (PCOS), diabetes, or previous pregnancy complications such as preeclampsia. Participants will have the opportunity to contribute to important research that could improve understanding of pregnancy complications and cardiovascular health in IVF patients. It's important to note that the trial is not yet recruiting, so interested individuals will need to wait for further announcements.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Autologous embryo transfer in programmed FET-cycle or modified-natural FET-cycle or
- • Planned donor egg transfer in programmed FET-cycle or modified-natural FET-cycle
- • Age \< 40 years
- • BMI \< 35
- • Primary diagnosis being unexplained infertility, male infertility or tubal factor
- • Singleton blastocyst transfer
- Exclusion Criteria:
- • PCOS
- • Essential hypertension
- • Diabetes Mellitus (type 1 or 2)
- • Known cardiac disease
- • Antiphospholipid syndrome, Lupus erythematosus, rheumatoid disease
- • Preelampsia, gestational hypertension, gestational diabetes or severe intrauterine growth restriction (IUGR) in any previous pregnancy
- • Smoking
- • Multiple pregnancy
- • Severe claustrophobia or any other contraindications to MRI
About Aalborg University Hospital
Aalborg University Hospital is a leading healthcare institution in Denmark, renowned for its commitment to advancing medical research and patient care. As a prominent clinical trial sponsor, the hospital actively engages in innovative studies aimed at improving health outcomes across various medical disciplines. With a focus on collaboration and interdisciplinary approaches, Aalborg University Hospital leverages its state-of-the-art facilities and expertise to conduct rigorous clinical trials, ensuring adherence to the highest ethical standards and regulatory requirements. The institution is dedicated to fostering a culture of research excellence, contributing valuable insights to the medical community and enhancing treatment options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aalborg, , Denmark
Patients applied
Trial Officials
Lise H Thomsen, MD, PhD
Study Chair
Department of Obstetrics and Gynecology, Aalborg University Hospital, Denmark
Anne N Sørensen, MD, PhD
Study Chair
Department of Obstetrics and Gynecology, Aalborg University Hospital, Denmark
Ulrik Kesmodel, Professor
Study Chair
The Fertility Unit, Department of Obstetrics and Gynecology, Aalborg University Hospital, Denmark
Peter Humaidan, Professor
Study Chair
The Fertility Clinic, Department of Obstetrics and Gynecology, Skive Region Hospital, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported